Oxolife, backed by Inveready, receives a 2.4M€ grant to develop a new treatment for infertility related to polycystic ovarian syndrome

by Inveready Asset Management

Oxolife, the Women’s Reproductive Health R&D biotech, has been awarded with a 2.4M€ grant from the Spanish Science and Innovation Ministry (Plan Estatal de Investigación Científica) to develop a...

Read more

Oxolife, a biotech company, raises 5 million euros for its Phase II Clinical Trial. Inveready leads the investment round together with CDTI, BStartup and HighStick, among other investors

by Inveready Asset Management

The biotech company Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Ass...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

ALBIA IMAP advises AKT on its sale to CI...

by Albia Capital Partners

CIE AUTOMOTIVE, Global supplier of components, assemblies and sub-asse...

Photos Stream